Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Depreciation & Amortization (CF) (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $77000.0 in Q4 2023.

  • For Q4 2023, Depreciation & Amortization (CF) rose 30.51% year-over-year to $77000.0; the TTM value through Dec 2023 reached $310000.0, up 233.33%, while the annual FY2025 figure was $311000.0, 1.63% up from the prior year.
  • Depreciation & Amortization (CF) reached $77000.0 in Q4 2023 per CGEM's latest filing, down from $80000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $81000.0 in Q2 2023 and bottomed at $9000.0 in Q3 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $32375.0, with a median of $15000.0 recorded in 2020.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 30.77% in 2022, then skyrocketed 788.89% in 2023.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $15000.0 in 2020, then dropped by 20.0% to $12000.0 in 2021, then skyrocketed by 391.67% to $59000.0 in 2022, then soared by 30.51% to $77000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $77000.0 in Q4 2023, $80000.0 in Q3 2023, and $81000.0 in Q2 2023.